Live Breaking News & Updates on Role Function Preventive

ABBVie today announced that the New England Journal of Medicine  has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine. The study, which enrolled adult participants experiencing 4 to 14 migraine days per month, found that all active treatment arms of atogepant 10 mg, 30 mg, and 60 mg once-daily . ....

United States , City Of , United Kingdom , Peter Goadsby , University Of California Los Angeles , Virtual Migraine Trust International Symposium , American Academy Of Neurology Annual Meeting , Drug Administration , International Classification Of Headache Disorders , Exchange Commission , King College , Migraine Research Foundation , New England Journal , Michael Gold , Migraine Specific Quality , Life Questionnaire , Role Function Restrictive , Daily Activities , Physical Impairment , Los Angeles , Migraine Trust International Symposium , Clinical Trials Plenary Session , Neurology Annual , Role Function Preventive , Emotional Function , Activity Impairment ,